Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Hurel Corporation Makes New Appointment to Board

Published: Tuesday, May 21, 2013
Last Updated: Tuesday, May 21, 2013
Bookmark and Share
Leading pharmaceutical executive and toxicologist Dr. James S. MacDonald appointed to Board of Directors.

Hurel Corporation announced the appointment of James S. MacDonald, PhD, DABT to the Company’s Board of Directors.  Dr. MacDonald is the former Executive Vice President of Preclinical Development of the Schering-Plough Research Institute (“SPRI”), which was the pharmaceutical development arm of Schering Corporation prior to its acquisition by Merck & Co. in 2009.

Over a career that has spanned more than three decades, Dr. MacDonald has brought hundreds of drug candidates into development, over thirty of which have become globally registered, major drugs, including Vasotec®, Zocor®, Primaxin®, Clinoril®, Prilosec®, Fosamax®, Clarinex®, Nasonex®, Vytorin®, and Victrelis®, among others.  Dr. MacDonald joined SPRI in 1994 as Senior Vice President, Drug Safety and Metabolism, and, over the next 14 years up until the time of the Merck acquisition, he played a leading role in building one of the most distinguished and effective drug development organizations in the world.  As co-chairman of SPRI’s Early Development Committee, he directed the movement of drug candidates from discovery research into and through the development process.  Previously Dr. MacDonald held positions of increasing responsibility at Merck, including Executive Director of Toxicology.  He received his Ph.D. in toxicology in 1975 from the University of Cincinnati and completed a post-doctoral fellowship at Vanderbilt University.  He became a diplomate of the American Board of Toxicology in 1980.

“Jim MacDonald’s track record of getting pharmaceuticals approved by FDA and onto the market speaks for itself,” said Robert Freedman, Hµrel’s Chairman and CEO.  “Hµrel is privileged to benefit from Jim’s extraordinary wisdom and experience, both as a scientist and as a drug development executive.  His guidance will be invaluable.  We welcome Jim to the Board as a colleague and friend.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Rates of Nonmedical Prescription Opioid Use Disorder Double in 10 Years
Researchers at NIH have found that the nonmedical use of prescription opioids has more than doubled among adults in the United States from 2001-2002 to 2012-2013.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
‘Human-on-a-Chip’ Could Replace Animal Testing
Researchers are developing a “human-on-a-chip,” a miniature external replication of the human body, integrating biology and engineering with a combination of microfluidics and multi-electrode arrays.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
‘Missing Tooth’ Hydrogels Handle Hard-to-Deliver Drugs
Rice University’s custom hydrogel traps water-avoiding molecules for slow delivery.
Copper is Key in Burning Fat
Berkeley Lab scientist says results could provide new target for obesity research.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
Identifying Side-Effects At Early Stages Of Drug Development
An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline (GSK).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!